With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., March 9, 2021 /PRNewswire/ The time of Tune In… Turn On… and Dropout psychedelics, such as certain, mushrooms and of course, LSD were not only not legal, but no researcher could even suggest studying the compounds… they were universally declared taboo. My, but how times have changed now that the baby boomers are old and want treatments for what life is bringing them now… new, effective treatments. Psychedelic medicine is one of the fastest growing markets. Psychedelic Medicines also called as hallucinogenics, are a group of substances including chemicals, such as LSD, and plants that are used in the treatment of various mental disorders such as resistant depression, panic disorder, opiate addiction, etc. These are used to change and enhance sensory perceptions, energy levels, thought pr
Article content
Prior to the pandemic, the lifetime prevalence of major depressive disorder in Canada was between 4.7-11.2 per cent, which has equated to a $51 billion burden on the Canadian economy through lost productivity, lowered quality of life, and related healthcare costs. Early reports suggest that these figures have grown significantly, with rates of depression symptoms and suicidal ideation tripling since the start of the pandemic with over half the population reporting worsened mental health due to the impact of the pandemic. Current treatment approaches such as antidepressants struggle with high drop-out, relapse, and non-adherence rates, as well as negligible improvements in symptoms. These issues have warranted an exploration of novel treatment approaches and there is a growing body of research that supports psychedelic-assisted therapy’s ability to address them.
How Sabina Pillai is championing the psychedelic drug revolution in Canada winnipegsun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from winnipegsun.com Daily Mail and Mail on Sunday newspapers.
Share:
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) Field Trip Health Ltd. (CSE:FTRP, FTRP.WT, OTCQX:FTRPF) (
Field Trip ), a leader in the development and delivery of psychedelic therapies, is pleased to announce it has entered into an agreement with Bloom Burton Securities Inc. (
Bloom Burton or the
Lead Underwriter ) on behalf of a syndicate of underwriters (together with the Lead Underwriter, the
Underwriters ), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis 7,692,310 common shares (the
Common Shares ) of the Company at a price of $6.50 per Common Share (the
Rise In Consumer Acceptance of Psychedelic Drug Therapies Is Quickly Increasing
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., Feb. 17, 2021 /PRNewswire/ Psychedelics are making their way out of the counterculture and back into the mainstream, with research and media interest in the mind-altering substances growing substantially. Some have even called psychedelics psychiatry s brave new world. The revitalization of psychedelics has occurred alongside a shift away from the research and development of traditional psychiatric medications by leading pharmaceutical companies. A report from Data Bridge Market Research reported that the global psychedelic drugs market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Growing prevalence of depression worldwide and increase in special designation from the regulatory authorities to the company to expedite the development process are the key factors for market g